Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06859099 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06859099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06859099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
April 1, 2025
Completion date
October 3, 2029
Enrollment
300 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

polyneuropathy, inflammatory demyelinating, chronic